MIRA PHARMACEUTICALS, INC.
MIRA · XNASCIK 1904286fmd_1QQXXJEGV0DMN3JJ269S1HTYMQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 18 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Net interest income | – | – | 0 | 0 |
| Research and development | 2 | 2 | 3 | 2 |
| Total operating expenses | 7 | 9 | 8 | 10 |
| Interest expense | 0 | 3 | (0) | – |
| Other non-operating income (expense) | – | – | 0 | 0 |
| Net income | (7) | (12) | (8) | (10) |
| Net income to common shareholders | – | – | (8) | (32) |